Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) or Intolerant to Entecavir

NCT04034368 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT04034368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04034368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) or Intolerant to Entecavir
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2019
Completion date
June 30, 2021
Enrollment
8 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbv